Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes

Yu Hsun Kao, Chen Chuan Cheng, Yao Chang Chen, Cheng Chih Chung, Ting I. Lee, Shih Ann Chen, Yi Jen Chen

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) plays an essential role in Ca2+ homeostasis and cardiac functions. The promoter region of SERCA2a has a high content of CpG islands; thus, epigenetic modification by inhibiting methylation can enhance SERCA2a expression in cardiomyocytes. Hydralazine, a drug frequently used in heart failure, is a potential DNA methylation inhibitor. We evaluated whether hydralazine can modulate Ca2+ handling through an increase in SERCA2a expression via regulating methylation. We used indo-1 fluorescence, real-time RT-PCR, immunoblotting, and methylation-specific PCR to investigate intracellular Ca2+, the expressions of RNA and protein, and methylation of SERCA2a in HL-1 cardiomyocytes with and without (control) the administration of hydralazine (1, 10, and 30 M) for 72 h. Hydralazine (10 and 30 M) increased the intracellular Ca2+ transients and SR Ca2+ contents. Hydralazine (10 and 30 M) decreased methylation in the SERCA2a promoter region and increased the RNA and protein expressions of SERCA2a. Additionally, hydralazine (10 and 30 M) decreased the expression of DNA methyltransferase 1. Moreover, treatment with hydralazine in isoproterenol-induced heart failure rats decreased the promoter methylation of SERCA2a and increased SERCA2a RNA expression. In conclusion, hydralazine-induced promoter demethylation may improve cardiac function through increasing SERCA2a and modulating calcium homeostasis in cardiomyocytes.

Original languageEnglish
Pages (from-to)1291-1297
Number of pages7
JournalLaboratory Investigation
Volume91
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Hydralazine
Calcium-Transporting ATPases
Sarcoplasmic Reticulum
Cardiac Myocytes
Homeostasis
Methylation
Calcium
RNA
Genetic Promoter Regions
Heart Failure
CpG Islands
Methyltransferases
DNA Methylation
Isoproterenol
Immunoblotting
Epigenomics
Real-Time Polymerase Chain Reaction
Proteins
Fluorescence
Polymerase Chain Reaction

Keywords

  • heart failure
  • hydralazine
  • intracellular calcium
  • methylation
  • sarcoplasmic reticulum Ca-ATPase

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes. / Kao, Yu Hsun; Cheng, Chen Chuan; Chen, Yao Chang; Chung, Cheng Chih; Lee, Ting I.; Chen, Shih Ann; Chen, Yi Jen.

In: Laboratory Investigation, Vol. 91, No. 9, 09.2011, p. 1291-1297.

Research output: Contribution to journalArticle

@article{d5dbb3a1e9834ec9af7f0ae42bdf9715,
title = "Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes",
abstract = "Sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) plays an essential role in Ca2+ homeostasis and cardiac functions. The promoter region of SERCA2a has a high content of CpG islands; thus, epigenetic modification by inhibiting methylation can enhance SERCA2a expression in cardiomyocytes. Hydralazine, a drug frequently used in heart failure, is a potential DNA methylation inhibitor. We evaluated whether hydralazine can modulate Ca2+ handling through an increase in SERCA2a expression via regulating methylation. We used indo-1 fluorescence, real-time RT-PCR, immunoblotting, and methylation-specific PCR to investigate intracellular Ca2+, the expressions of RNA and protein, and methylation of SERCA2a in HL-1 cardiomyocytes with and without (control) the administration of hydralazine (1, 10, and 30 M) for 72 h. Hydralazine (10 and 30 M) increased the intracellular Ca2+ transients and SR Ca2+ contents. Hydralazine (10 and 30 M) decreased methylation in the SERCA2a promoter region and increased the RNA and protein expressions of SERCA2a. Additionally, hydralazine (10 and 30 M) decreased the expression of DNA methyltransferase 1. Moreover, treatment with hydralazine in isoproterenol-induced heart failure rats decreased the promoter methylation of SERCA2a and increased SERCA2a RNA expression. In conclusion, hydralazine-induced promoter demethylation may improve cardiac function through increasing SERCA2a and modulating calcium homeostasis in cardiomyocytes.",
keywords = "heart failure, hydralazine, intracellular calcium, methylation, sarcoplasmic reticulum Ca-ATPase",
author = "Kao, {Yu Hsun} and Cheng, {Chen Chuan} and Chen, {Yao Chang} and Chung, {Cheng Chih} and Lee, {Ting I.} and Chen, {Shih Ann} and Chen, {Yi Jen}",
year = "2011",
month = "9",
doi = "10.1038/labinvest.2011.92",
language = "English",
volume = "91",
pages = "1291--1297",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+-ATPase and calcium homeostasis in cardiac myocytes

AU - Kao, Yu Hsun

AU - Cheng, Chen Chuan

AU - Chen, Yao Chang

AU - Chung, Cheng Chih

AU - Lee, Ting I.

AU - Chen, Shih Ann

AU - Chen, Yi Jen

PY - 2011/9

Y1 - 2011/9

N2 - Sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) plays an essential role in Ca2+ homeostasis and cardiac functions. The promoter region of SERCA2a has a high content of CpG islands; thus, epigenetic modification by inhibiting methylation can enhance SERCA2a expression in cardiomyocytes. Hydralazine, a drug frequently used in heart failure, is a potential DNA methylation inhibitor. We evaluated whether hydralazine can modulate Ca2+ handling through an increase in SERCA2a expression via regulating methylation. We used indo-1 fluorescence, real-time RT-PCR, immunoblotting, and methylation-specific PCR to investigate intracellular Ca2+, the expressions of RNA and protein, and methylation of SERCA2a in HL-1 cardiomyocytes with and without (control) the administration of hydralazine (1, 10, and 30 M) for 72 h. Hydralazine (10 and 30 M) increased the intracellular Ca2+ transients and SR Ca2+ contents. Hydralazine (10 and 30 M) decreased methylation in the SERCA2a promoter region and increased the RNA and protein expressions of SERCA2a. Additionally, hydralazine (10 and 30 M) decreased the expression of DNA methyltransferase 1. Moreover, treatment with hydralazine in isoproterenol-induced heart failure rats decreased the promoter methylation of SERCA2a and increased SERCA2a RNA expression. In conclusion, hydralazine-induced promoter demethylation may improve cardiac function through increasing SERCA2a and modulating calcium homeostasis in cardiomyocytes.

AB - Sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) plays an essential role in Ca2+ homeostasis and cardiac functions. The promoter region of SERCA2a has a high content of CpG islands; thus, epigenetic modification by inhibiting methylation can enhance SERCA2a expression in cardiomyocytes. Hydralazine, a drug frequently used in heart failure, is a potential DNA methylation inhibitor. We evaluated whether hydralazine can modulate Ca2+ handling through an increase in SERCA2a expression via regulating methylation. We used indo-1 fluorescence, real-time RT-PCR, immunoblotting, and methylation-specific PCR to investigate intracellular Ca2+, the expressions of RNA and protein, and methylation of SERCA2a in HL-1 cardiomyocytes with and without (control) the administration of hydralazine (1, 10, and 30 M) for 72 h. Hydralazine (10 and 30 M) increased the intracellular Ca2+ transients and SR Ca2+ contents. Hydralazine (10 and 30 M) decreased methylation in the SERCA2a promoter region and increased the RNA and protein expressions of SERCA2a. Additionally, hydralazine (10 and 30 M) decreased the expression of DNA methyltransferase 1. Moreover, treatment with hydralazine in isoproterenol-induced heart failure rats decreased the promoter methylation of SERCA2a and increased SERCA2a RNA expression. In conclusion, hydralazine-induced promoter demethylation may improve cardiac function through increasing SERCA2a and modulating calcium homeostasis in cardiomyocytes.

KW - heart failure

KW - hydralazine

KW - intracellular calcium

KW - methylation

KW - sarcoplasmic reticulum Ca-ATPase

UR - http://www.scopus.com/inward/record.url?scp=80052275311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052275311&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2011.92

DO - 10.1038/labinvest.2011.92

M3 - Article

C2 - 21747360

AN - SCOPUS:80052275311

VL - 91

SP - 1291

EP - 1297

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 9

ER -